Japanese Journal of Cancer and Chemotherapy最新文献_第10页

[A Case of Achieving Radical Cure While Preserving the Function of the Pancreatic Body in a Patient with Double Primary Tumors of Pancreatic Head Cancer and Pancreatic Tail NEN]. [1例胰头癌和胰尾癌双原发肿瘤患者在保持胰腺功能的同时实现根治]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-01-01

Ryota Kogure, Riki Ninomiya, Kazuhiro Mori, Rihito Nagata, Akifumi Kimura, Masahiko Komagome, Akira Maki, Yoshifumi Beck

{"title":"[A Case of Achieving Radical Cure While Preserving the Function of the Pancreatic Body in a Patient with Double Primary Tumors of Pancreatic Head Cancer and Pancreatic Tail NEN].","authors":"Ryota Kogure, Riki Ninomiya, Kazuhiro Mori, Rihito Nagata, Akifumi Kimura, Masahiko Komagome, Akira Maki, Yoshifumi Beck","doi":"","DOIUrl":"","url":null,"abstract":"While pancreatic ductal adenocarcinoma (PDAC) originates from exocrine cells of the pancreas, pancreatic neuroendocrine neoplasms (PNENs) arise from pancreatic neuroendocrine cells. The concurrent presence of an exocrine pancreatic tumor and a pancreatic neuroendocrine tumor is referred to broadly as a pancreatic collision tumor. In cases where the lesions are spatially distant, they are termed as multiple primary tumors, a relatively uncommon occurrence. For both, surgical radical resection contributes to improved prognosis. Therefore, accurate evaluation of factors such as tumor number and localization is essential to determine the necessity of radical resection. However, compared to solitary tumors, this often leads to more extensive surgery. We performed subtotal stomach-preserving pancreaticoduodenectomy and distal pancreatectomy (including splenectomy) for a male patient in his 60s with pancreatic head adenocarcinoma and pancreatic tail neuroendocrine tumor (NET) G2. We sought to achieve an insulin-free outcome by preserving the function of the pancreatic body. We report a case where surgical techniques were optimized to enhance postoperative quality of life.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 1","pages":"64-66"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Advanced Gastric Cancer with Massive Lymph Node Metastases Greatly Decreased in Size after Chemotherapy with Nivolumab and SOX]. [尼武单抗联合SOX化疗后晚期胃癌淋巴结转移肿大缩小1例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-01-01

Ruiichiro Morita, Yukihiro Kato, Hanae Matsuda, Takuya Kikukawa, Atsushi Isihara, Yasunori Matsuda, Seikann Miyashita, Masahiro Nishikawa, Takahiro Uenishi, Yuuko Kuwae, Masahiko Osawa

{"title":"[A Case of Advanced Gastric Cancer with Massive Lymph Node Metastases Greatly Decreased in Size after Chemotherapy with Nivolumab and SOX].","authors":"Ruiichiro Morita, Yukihiro Kato, Hanae Matsuda, Takuya Kikukawa, Atsushi Isihara, Yasunori Matsuda, Seikann Miyashita, Masahiro Nishikawa, Takahiro Uenishi, Yuuko Kuwae, Masahiko Osawa","doi":"","DOIUrl":"","url":null,"abstract":"A 81-year-old woman was referred to our department for further examination and treatment after upper gastrointestinal endoscopy revealed a type 3 tumor in the antrum. CT scan revealed a primary tumor with extramural invasion in the antrum and large lymph nodes bordering the pancreas, as well as in the right side of cardia. A diagnosis of advanced gastric cancer cT4aN2M0, cStage Ⅲ was made. She was administered chemotherapy with nivolumab and SOX. After 2 courses of treatment, CT scan showed marked reduction of the primary tumor and lymph nodes. Therefore, laparoscopic gastrectomy(D2 dissection+Roux-en-Y reconstruction)was performed. Histopathological findings showed that the primary tumor was confined to the sub serosal tissue and no lymph node metastases were observed. The patient is currently alive without recurrence and treated with S-1 monotherapy. Chemotherapy with nivolumab and SOX is considered to be an effective treatment strategy for advanced gastric cancer with advanced lymph node metastases.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 1","pages":"73-75"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Significance of Conversion Surgery in Colorectal Cancer]. 【结直肠癌转化手术的意义】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-01-01

Yukihide Kanemitsu, Hiroshi Nagata, Yasuyuki Takamizawa, Konosuke Moritani, Shunsuke Tsukamoto

引用次数: 0

[Current Status and Issue of Emesis and Vomiting Caused by Trastuzumab Deruxtecan]. [曲妥珠单抗德鲁司替康致呕吐的现状及问题]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-01-01

Ai Soma, Fumie Fujisawa, Ayako Higuchi, Yusa Togashi, Azusa Taniguchi, Yuri Oyama, Yukiko Seto, Sone Park, Jun Okuno, Noriyuki Watanabe, Saki Matsui, Tetsuhiro Yoshinami, Minako Nishio, Mikiya Ishihara, Toshinari Yagi, Takahiro Nakayama

{"title":"[Current Status and Issue of Emesis and Vomiting Caused by Trastuzumab Deruxtecan].","authors":"Ai Soma, Fumie Fujisawa, Ayako Higuchi, Yusa Togashi, Azusa Taniguchi, Yuri Oyama, Yukiko Seto, Sone Park, Jun Okuno, Noriyuki Watanabe, Saki Matsui, Tetsuhiro Yoshinami, Minako Nishio, Mikiya Ishihara, Toshinari Yagi, Takahiro Nakayama","doi":"","DOIUrl":"","url":null,"abstract":"Emesis and vomiting are the most common adverse events related to trastuzumab deruxtecan(T-DXd). T-DXd is listed as a moderate emetogenic chemotherapy(MEC)agent in the latest guidelines for the appropriate use of antiemetic drugs in Japan; however, the National Comprehensive Cancer Network Guidelines regard it as a highly emetogenic chemotherapy (HEC)agent. We investigated the risk factors for chemotherapy-induced nausea and vomiting(CINV)associated with T-DXd by analyzing data from 40 patients with advanced breast cancer(median age, 56 years)were receiving T-DXd administration between June 2020 and July 2023. CINV was graded using CTCAE v5.0. All patients were treated with antiemetic therapy consisting of a 5-HT3 receptor antagonist(5-HT3RA)and dexamethasone(DEX); 3 patients also received an NK1 receptor antagonist(NK1RA). Emesis was observed in 23(57.5%)(Grade≥2 in 7), and vomiting in 2 patients(5.0%, Grade 1). Emesis occurred >1 day after T-DXd administration in 78.3% and lasted for ≥7 days in 69.6%. These symptoms may be characteristic of T-DXd-related CINV. Antiemetic therapy for CINV in HEC may be considered to control T-DXd-associated CINV in patients aged<50 years or in those who did not achieve sufficient curative effects with MEC.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 1","pages":"31-35"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Anaplastic Carcinoma of the Pancreas of the Spindle Cell Type with Rapid Growth after Distal Pancreatectomy-A Case Report]. 远端胰腺切除术后快速生长梭形细胞型胰腺间变性癌1例报告。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-01-01

Hisafumi Akimoto, Suefumi Aosasa, Tatsuro Ishikawa, Makoto Uchiyama, Yasushi Takafuji, Takuya Kato, Takahiro Shimauchi, Kazutsugu Iwamoto, Hiroshi Yamaguchi, Kenji Warigaya, Satoshi Ono

引用次数: 0

[Conversion Surgery for Pancreatic Cancer]. [胰腺癌转化手术]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-01-01

Masanori Horikawa, Mina Fukasawa, Juri Machi, Haruki Urushihara, Yuria Furuhara, Akihiro Sunakawa, Koutarou Yamamoto, Hiromitsu Kusunoki, Nana Kimura, Ryo Muranushi, Yoshihiro Shirai, Katsuhisa Hirano, Toru Watanabe, Kazuto Shibuya, Isaku Yoshioka, Tsutomu Fujii

{"title":"[Conversion Surgery for Pancreatic Cancer].","authors":"Masanori Horikawa, Mina Fukasawa, Juri Machi, Haruki Urushihara, Yuria Furuhara, Akihiro Sunakawa, Koutarou Yamamoto, Hiromitsu Kusunoki, Nana Kimura, Ryo Muranushi, Yoshihiro Shirai, Katsuhisa Hirano, Toru Watanabe, Kazuto Shibuya, Isaku Yoshioka, Tsutomu Fujii","doi":"","DOIUrl":"","url":null,"abstract":"Pancreatic cancer is known as a disease with an extremely poor prognosis. Although surgery is the only curative treatment, most pancreatic cancer is already advanced at the time of diagnosis. With advances in multidisciplinary treatment such as chemotherapy, radiation therapy, and heavy-ion therapy, more cases of unresectable(UR)pancreatic cancer are being treated with surgery in recent years. Therefore, the term\"conversion surgery\"has been newly included in the 8th edition of the General Rules for Study of Pancreatic Cancer, and the treatment strategy for UR pancreatic cancer has entered a new phase. Conversion surgery for UR-LA pancreatic cancer is expected to be effective as the indications for chemoradiation and heavy-ion radiation therapy expand. On the other hand, UR-LA pancreatic cancer is not only a locally advanced disease but also a systemic disease, and there have been reports of patients with early postoperative recurrence, so the indication for surgery remains a controversial field. Furthermore, there are increasing reports of conversion surgery for UR-M pancreatic cancer. There are concerns about complications and increased mortality due to extended resection, and early recurrence, so usefulness is not clear at present. Among UR-M, positive peritoneal washing cytology(CY1)is considered to be a preliminary stage of peritoneal dissemination, and is now treated as distant metastasis since the 8th edition of General Rules. CY-positive pancreatic cancer is easier to control than other distant metastases, and CY-negative conversion is expected to be equivalent to that of patients with CY0 at the initial diagnosis. Further evidence for multidisciplinary treatment, including conversion surgery, is expected to be accumulated.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 1","pages":"19-24"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Two Cases of Cholangiolocellular Carcinoma with Difficult Preoperative Diagnosis]. 术前诊断困难的胆管细胞癌2例

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-01-01

Yoshiteru Katsura, Koji Hayashi, Narumi Sawamura, Risa Kawamoto, Yo Akazawa, Ryuta Ueda, Masahiro Koh, Akio Hara, Hiroshi Takeyama, Natsumi Tanaka, Naomi Urano, Shu Okamura, Setsuko Yoshioka, Hideoki Yokouchi, Chikara Ebisui

引用次数: 0

[A Case of Radical Resection of Intraductal Papillary Mucinous Adenocarcinoma Complicated by Obstructive Pancreatitis]. 导管内乳头状粘液腺癌合并梗阻性胰腺炎根治性切除1例

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-01-01

Kenji Sakai, Kunihito Gotoh, Naoki Hama, Reishi Toshiyama, Mao Osaki, Shinji Tokuyama, Masaaki Yamamoto, Kenji Kawai, Yusuke Takahashi, Atushi Takeno, Takeshi Kato, Motohiro Hirao

引用次数: 0

[pT2 Gallbladder Cancer with Suspected Intrapancreatic Bile Duct Recurrence Four Years Postoperatively-A Case Report]. pT2胆囊癌术后4年疑似胰内胆管复发1例。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-01-01

Shigeru Fujisaki, Motoi Takashina, Ryouichi Tomita, Kenichi Sakurai, Yukiyasu Okamura

{"title":"[pT2 Gallbladder Cancer with Suspected Intrapancreatic Bile Duct Recurrence Four Years Postoperatively-A Case Report].","authors":"Shigeru Fujisaki, Motoi Takashina, Ryouichi Tomita, Kenichi Sakurai, Yukiyasu Okamura","doi":"","DOIUrl":"","url":null,"abstract":"We report a case of intrapancreatic bile duct solitary recurrence 4 years postoperatively for pT2 gallbladder cancer. A 58-year-old woman underwent laparoscopic cholecystectomy for a growing gallbladder polyp. Her histopathological findings included well-differentiated adenocarcinoma, pT2a, ly0, v0, ne0, pCM0, pEM0, R0. Consequently, gallbladder bed resection, extrahepatic bile duct resection, choledochojejunostomy, and lymph node dissection were performed. Following which, residual cancer was not reported. Postoperatively, abdominal computed tomography(CT)scans were performed at 6-month intervals. A 3-cm mass with poor contrast was observed in the pancreatic head 4 years postoperatively without main pancreatic duct dilation or pancreatic parenchymal atrophy, and the mass was considered as a recurrent nodule of gallbladder cancer. The recurrent mass could no longer be identified after three courses of GEM+CDDP combination therapy. Subsequently, the disease was determined to be curable, and a pancreaticoduodenectomy was performed. Her postoperative course was uneventful, and the patient was discharged after 30 days. A clearly demarcated white nodular mass measuring 5 mm in diameter was observed in the posterior part of the pancreas, which was a poorly differentiated adenocarcinoma. In this case, the tumor was macroscopically and histologically atypical for primary cancer and was considered a gallbladder cancer recurrence with its main site in the bile duct.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 1","pages":"79-81"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Conversion Surgery for Initially Unresectable Hepatocellular Carcinoma]. [原发性不可切除肝癌的转化手术]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-01-01

Takamichi Ishii, Tomoaki Yoh, Takahiro Nishio, Hiroto Nishino, Hidenobu Kojima, Satoshi Ogiso, Takayuki Anazawa, Kazuyuki Nagai, Yoichiro Uchida, Takashi Ito, Etsuro Hatano

{"title":"[Conversion Surgery for Initially Unresectable Hepatocellular Carcinoma].","authors":"Takamichi Ishii, Tomoaki Yoh, Takahiro Nishio, Hiroto Nishino, Hidenobu Kojima, Satoshi Ogiso, Takayuki Anazawa, Kazuyuki Nagai, Yoichiro Uchida, Takashi Ito, Etsuro Hatano","doi":"","DOIUrl":"","url":null,"abstract":"Conversion surgery means surgery for initially unresectable tumors which are converted to resectable tumors by multidisciplinary treatment. Since the introduction of highly effective drug therapies including immune checkpoint inhibitors for hepatocellular carcinoma(HCC), conversion surgery for HCC has become a common experience. Recently, the Japanese Expert Consensus 2023 have reported on the oncological criteria of resectability for HCC, allowing us to use common terms to describe unresectable HCC, which had been ambiguously defined in the past. HCC cases are classified into 3 criteria, based on the tumor number and size, the degree of vascular invasion, and the degree of extrahepatic involvement. The 3 criteria are R(resectable; oncological status for which surgery alone may offer clearly better survival outcomes compared to the other treatment), BR1(borderline resectable 1; oncological status for which surgical intervention as a part of multidisciplinary treatment may offer survival benefit), and BR2(borderline resectable 2; initially unsuitable for resection: oncological status for which efficacy of surgery is indeterminate and surgical indication should be carefully determined under the standard multidisciplinary management of HCC). Whether conversion surgery improves prognosis under the assumption that nonsurgical treatment such as drug therapy has been successful is a question for further investigation.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 1","pages":"25-29"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0